Switches from the lymphoid to myeloid lineage during B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treatment are considered rare and thus far have been detected in MLL-rearranged leukemia. Here, we describe a novel BCP-ALL subset, switching BCP-ALL or swALL, which demonstrated monocytosis early during treatment. Despite their monocytic phenotype, 'monocytoids' share immunoreceptor gene rearrangements with leukemic B lymphoblasts. All swALLs demonstrated BCP-ALL with CD2 positivity and no MLL alterations, and the proportion of swALLs cases among BCP-ALLs was unexpectedly high (4%). The upregulation of CEBPα and demethylation of the CEBPA gene were significant in blasts at diagnosis, prior to the time when most of the switching occurs. Intermediate stages between CD14(neg)CD19(pos)CD34(pos) B lymphoblasts and CD14(pos)CD19(neg)CD34(neg) 'monocytoids' were detected, and changes in the expression of PAX5, PU1, M-CSFR, GM-CSFR and other genes accompanied the switch. Alterations in the Ikaros and ERG genes were more frequent in swALL patients; however, both were altered in only a minority of swALLs. Moreover, switching could be recapitulated in vitro and in mouse xenografts. Although children with swALL respond slowly to initial therapy, risk-based ALL therapy appears the treatment of choice for swALL. SwALL shows that transdifferentiating into monocytic lineage is specifically associated with CEBPα changes and CD2 expression.

Centre of Oncocytogenetics Institute of Clinical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague Czech Republic

Children's Cancer Research Institute and St Anna Children's Hospital Department of Pediatrics Medical University of Vienna Vienna Austria

Department of Clinical Hematology University Hospital Motol Prague Czech Republic

Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Pediatrics University Hospital Schleswig Holstein Kiel Germany

Division of Oncology and Children's Research Center University Children's Hospital University of Zurich Zurich Switzerland

Northern Institute for Cancer Research Newcastle University Newcastle UK

University of Michigan Medical School Department of Pathology Ann Arbor MI USA

See more in PubMed

Cancer Chemother Pharmacol. 2003 Jun;51(6):465-73 PubMed

Leukemia. 2002 Jul;16(7):1233-58 PubMed

Blood. 2011 Aug 18;118(7):1854-64 PubMed

Cytometry B Clin Cytom. 2008 May;74(3):150-5 PubMed

Leuk Res. 2009 Jul;33(7):1005-8 PubMed

J Immunol. 2009 Jun 15;182(12):7672-80 PubMed

Leukemia. 1995 Dec;9(12):2023-6 PubMed

Blood. 2009 Mar 26;113(13):3088-91 PubMed

Blood. 2008 Jun 15;111(12):5433-9 PubMed

Mol Cell Biol. 1995 Oct;15(10):5830-45 PubMed

Cancer Genet Cytogenet. 2006 Jul 15;168(2):146-9 PubMed

Br J Haematol. 2010 Sep;150(5):621-3 PubMed

Nat Immunol. 2006 Oct;7(10):1116-24 PubMed

Crit Rev Oncog. 2011;16(1-2):93-102 PubMed

Haematologica. 2010 Jun;95(6):928-35 PubMed

Cancer Res. 2004 Aug 1;64(15):5245-50 PubMed

Pediatr Blood Cancer. 2010 Jan;54(1):62-70 PubMed

J Immunol. 2005 Aug 15;175(4):2495-500 PubMed

Leuk Res. 2009 Nov;33(11):e195-8 PubMed

Blood. 2007 Apr 15;109(8):3451-61 PubMed

Leuk Res. 2010 Feb;34(2):e71-3 PubMed

Blood. 2010 Apr 22;115(16):3206-14 PubMed

Am J Hematol. 2012 Sep;87(9):890-7 PubMed

Blood. 2007 Nov 1;110(9):3136-42 PubMed

Nat Immunol. 2001 Jan;2(1):83-8 PubMed

Int J Hematol. 2011 Feb;93(2):247-252 PubMed

Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 PubMed

Cancer Cell. 2002 Mar;1(2):133-43 PubMed

Blood. 2010 Jun 10;115(23):4798-809 PubMed

Leukemia. 2009 May;23(5):944-51 PubMed

Br J Haematol. 2011 Jan;152(2):141-54 PubMed

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12944-9 PubMed

Immunol Rev. 2010 Nov;238(1):23-36 PubMed

Pediatr Blood Cancer. 2013 Mar;60(3):420-7 PubMed

Leukemia. 2014 Jan;28(1):70-7 PubMed

J Hematop. 2009 May 09;2(3):135-41 PubMed

Leukemia. 2014 Jan;28(1):182-5 PubMed

Int J Clin Oncol. 2010 Feb;15(1):112-5 PubMed

Oncogene. 2006 Jun 22;25(26):3735-44 PubMed

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17016-21 PubMed

Pediatr Dev Pathol. 2010 May-Jun;13(3):225-37 PubMed

Lancet. 2007 Jul 21;370(9583):240-250 PubMed

Cell. 2004 May 28;117(5):663-76 PubMed

Leukemia. 2007 Apr;21(4):604-11 PubMed

Leukemia. 2005 Jun;19(6):1092-4 PubMed

J Immunol. 2003 Jul 15;171(2):524-7 PubMed

Genes Chromosomes Cancer. 2004 Jan;39(1):88-92 PubMed

Nat Immunol. 2008 Aug;9(8):927-36 PubMed

N Engl J Med. 2009 Jan 29;360(5):470-80 PubMed

Leukemia. 2004 May;18(5):934-8 PubMed

Leukemia. 2008 May;22(5):989-97 PubMed

Br J Haematol. 2001 Jun;113(3):757-62 PubMed

Blood. 1997 Apr 1;89(7):2488-93 PubMed

Cell. 2006 Aug 25;126(4):755-66 PubMed

NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk

DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch

CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia

ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity

New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemia

Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

Recent advances in the management of pediatric acute lymphoblastic leukemia

Reprogramming of B cell acute lymphoblastic leukemia cells: Do we need to shoot a moving target?